The San Diego Union-Tribune's Keith Darcé recently spoke with Illumina CEO Jay Flatley about the company's share in the sequencing market, its lowered whole-genome sequencing price, its plans to develop diagnostic tests for certain cancers, and its recent involvement with the US Food and Drug Administration's push to regulate DTC genetic testing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.